# Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

> **NCT01776411** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mundipharma K.K.** · enrollment: 49 (estimated)

## Conditions studied

- Recurrent or Refractory PTCL

## Interventions

- **DRUG:** forodesine hydrochloride

## Key facts

- **NCT ID:** NCT01776411
- **Lead sponsor:** Mundipharma K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2016-03
- **Final completion:** 2017-04-26
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2017-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01776411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01776411, "Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01776411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*